CARsgen Therapeutics Announces Promising Results for CAR-T Therapies CT0596 and CT1190B

CARsgen Therapeutics Unveils Positive Clinical Data for CAR-T Products

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a pioneer in CAR T-cell therapies, has recently reported promising results from its clinical trials involving the allogeneic CAR-T products CT0596 and CT1190B. These products are designed to combat relapsed or refractory multiple myeloma (R/R MM) and non-Hodgkin lymphoma (R/R NHL), respectively.

Overview of CT0596

CT0596 is a BCMA-targeted CAR-T therapy developed on CARsgen's exclusive THANK-u Plus™ platform. It is currently being tested in investigator-initiated trials focusing on malignant plasma cell neoplasms. As of June 24, 2025, eight patients have been reported to have received CT0596 in an ongoing clinical trial (NCT06718270). With a median of 4.5 prior therapy lines and some having previous exposure to various treatment classes, the therapy appears to yield exciting results.

In the trial, six out of eight evaluable patients achieved a partial or complete response, some exhibiting stringent complete response (sCR). Importantly, no dose-limiting toxicities were noted, and the adverse effects experienced were manageable, primarily categorized as Grade 1 cytokine release syndrome (CRS).

Data on CT1190B

Moving on to CT1190B, which targets both CD19 and CD20, this CAR-T cell therapy is being evaluated in multiple trials for R/R NHL. The up-to-date clinical data from trials (NCT07053670, NCT06734871) indicate that, as of October 17, 2025, 14 patients have been enrolled. The initial results showcase a remarkable overall response rate (ORR) of 83.3%, with several patients achieving complete responses (CR).

Substantial lymphocyte expansion was observed in these patients, underscoring CT1190B's potential effectiveness. The product's primary safety signals included CRS, cytopenia, and infections, but no severe adverse reactions such as immune effector cell-associated neurologic syndrome (ICANS) or graft versus host disease (GVHD) were noted.

Future Directions

Both CT0596 and CT1190B are set to advance through clinical testing, with CARsgen Therapeutics aiming to expand their use into additional plasma cell diseases and autoimmune disorders. The company plans to file an Investigational New Drug (IND) application for CT0596 in late 2025 and continues to refine its approaches to therapy development, ensuring both safety and efficacy remain at the forefront of its clinical endeavors.

CARsgen is committed to addressing the unmet clinical needs in the oncology field through innovative research and targeted therapies. With their established efficiencies from target discovery to commercialization, CARsgen Therapeutics strives to elevate its position in the biopharmaceutical landscape, providing transformative solutions for patients battling cancer and autoimmune diseases worldwide.

In a rapidly evolving field, CARsgen’s advancements in CAR-T therapies bring renewed hope to patients with limited treatment options. As the studies progress, further data will become available, framing a clearer picture of the future of CAR-T cell therapies.